A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study
Van Cheng, BS*,
Radmila Kazanagra, MD*,
Alex Garcia, LVN*,
Leslie Lenert, MD*  ,
Padma Krishnaswamy, MD*,
Nancy Gardetto, NP*,
Paul Clopton, BS* and
Alan Maisel, MD, FACC*
* Division of Cardiology, Veteran’s Affairs Medical Center, San Diego, California, USA
Department of Medicine, University of California, San Diego, California, USA
View larger version (26K):
[in a new window]
|
Figure 1 B-type natriuretic peptide levels and NYHA classification before and after treatment in relation to end points or no end points (successful treatment). Each value represents mean ± SEM and is analyzed by analysis of variance. BNP = B-type natriuretic peptide; NYHA = New York Heart Association.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 The relation between end points and rising versus falling BNP levels during treatment. Values are given as percentages and analyzed by chi-square analysis. BNP = B-type natriuretic peptide (p < 0.001).
|
|
View larger version (30K):
[in a new window]
|
Figure 3 Receiver operating characteristic curves for patients with decompensated congestive heart failure compares the sensitivity and specificity of BNP measurements to 30-day readmission rates. Discrete cut-points are labeled. The AUC (C-statistic) was 0.72 for readmission. Sensitivity, specificity, positive and negative predictive values and accuracy are recorded for each cut-point of the receiver operating characteristic curve. AUC = area under the curve; BNP = B-type natriuretic peptide.
|
|
|
